Skip to content

PHARDA: value indication

Roughly what is an SME worth on what it filed? A range from its adjusted equity and its earnings, with your own assumptions, recalculated as you go.

Value indication

PHARDA

BE 0474.979.207
NACE 47.730, Retail sale of pharmaceutical products
latest balance sheet 30-09-2025indication, not a valuation or advice

Indicative value of the equity

Indication, not a valuation or advice
€466,481 to €585,808

Midpoint €516,201 · 50% capitalised earnings, 50% adjusted equity

Adjusted equity €336,326
Capitalised earnings €596,636 to €835,290
Indication €466,481 to €585,808

Your assumptions

Capitalised earnings
%

The return a buyer expects on the money put in. Higher for more risk. The range also computes with 2 points more and less.

Adjust the equity
Blend
50%
Optional: your own multiple

Checked holds no market prices, so it suggests no multiple. If you have one from a transaction or a study, the tool applies it to the filed EBITDA less the net financial debt.

Adjusted equity

balance sheet 30-09-2025
Equity (10/15)
€336,326
Revaluation of assets
€0
Deferred tax on the revaluation
€0
Other adjustment
€0
Adjusted equity
€336,326

Capitalised earnings

net result for the year (9904)
2025
€113,407
2024
€79,702
2023
€57,479
2022
€96,043
2021
€16,226
Average result
€83,529
Divided by the capitalisation rate
14% / 12% / 10%
Capitalised earnings
€596,636 / €696,075 / €835,290

What this indication leaves out

  • Market prices and comparable transactions: Checked does not hold them.
  • Anything after the latest accounts, and items off the balance sheet (guarantees, leases, disputes).
  • The real value of buildings, stock and receivables: enter your own revaluation or adjustment.
  • The owner's role in the business, synergies for a buyer and the tax consequences of a sale.

For a valuation to decide on: a company auditor or a certified accountant.

Source: filed annual accounts (NBB), latest balance sheet at 30 September 2025. Prepared on 28 September 2026 via checked.be. Indication, not a valuation or advice.